



200 Somerset Corporate Blvd., 8th Floor  
Bridgewater, New Jersey 08807-2862  
Tel 908-393-8229  
Fax 908-393-8249

**Timothy S. Ayers**  
Associate General Counsel

May 31, 2007

Minnesota Board of Pharmacy  
2829 University Ave. SE, Suite 530  
Minneapolis, MN 55414-3253



**Re: Wholesale Drug Distributor Disclosures**

To Whom It May Concern:

Abraxis BioScience, Inc. ("Abraxis") is a biopharmaceutical company dedicated to meeting the needs of critically ill patients. Specifically, Abraxis develops, manufactures, and markets drugs for the treatment of cancer and other life-threatening diseases. These drugs are available by prescription to the residents of Minnesota.

Pursuant to MINN. STAT. §151.47, Abraxis was required to submit marketing disclosure reports to the Minnesota Board of Pharmacy for years 2005 and 2006 but failed to do so. Abraxis notified the Minnesota Board of Pharmacy about this deficiency by letter dated May 1, 2007.

### **Reporting Requirements**

MINN. STAT. § 151.47(f) requires wholesale drug distributors to file with the Minnesota Board of Pharmacy an annual report identifying "all payments, honoraria, reimbursement or other compensation authorized under section 151.461, clauses (3) to (5), paid to practitioners in Minnesota during the preceding calendar year." Additionally, the Minnesota law requires wholesale drug distributors to identify "the nature and value of any payments totaling \$100 or more, to a particular practitioner during the year, and shall identify the practitioner." This report is due annually by May 1<sup>st</sup>.

### **Reports Filed with the Minnesota Board of Pharmacy for Years 2005 and 2006**

In an effort to complete the filing of the 2005 and 2006 reports, Abraxis underwent an expedited examination of all readily available data regarding payments and other compensation to healthcare practitioners in Minnesota. The relevant data from this data set has been compiled and the reports for years 2005 and 2006 completed on the form supplied by the Minnesota Board of Pharmacy. These reports are enclosed with this letter.


Consistent with MINN. STAT. § 151.47, certain expenditures which are exempt from disclosure were not included. These expenditures are professional samples of a drug intended for free distribution to patients; items with a total combined retail value, in any calendar year, of not more than \$50; publications and educational materials; or salaries or other benefits paid to employees.

Abraxis BioScience  
Minnesota Wholesale Drug Distributor Disclosures, MINN. STAT. § 151.47  
May 31, 2007

Abraxis has made every effort to disclose all available data in the format required by MINN. STAT. § 151.47 and the Minnesota Board of Pharmacy. However, as noted in our previous correspondence, Abraxis is aware that a more robust collection and reporting process needs to be institutionalized in order to meet all reporting requirements. Some of the reporting categories, such as payments to practitioners for research, were not readily available for the years 2005 and 2006. Abraxis is currently implementing policies and procedures to ensure that this data is collected and reported in future reporting periods. Abraxis is taking all necessary steps to ensure compliance with all requirements of MINN. STAT. § 151.47.

We will make ourselves available at a time that is convenient for you if you would like to discuss this matter further. Please contact me if you have any questions or if you would like to schedule a meeting or conference call.

Sincerely,

A handwritten signature in black ink, appearing to read 'T.S. Ayers', with a stylized flourish extending from the end.

Timothy S. Ayers  
Associate General Counsel

<b>NAME OF WHOLESALE DRUG DISTRIBUTOR/MANUFACTURER</b> Abraxis Bioscience Inc.		<b>ADDRESS OF WHOLESALE DRUG DISTRIBUTOR/MANUFACTURER</b> 11755 Wilshire Blvd. Suite 2000, 20 <sup>th</sup> Floor, Los Angeles, CA 90025	
<b>MN BOARD OF PHARMACY LICENSE NUMBER</b> Abraxis BioScience- Manufacturer #460011	<b>MINNESOTA STATUTES REQUIRE WHOLESALE DISTRIBUTORS TO FILE WITH THE BOARD OF PHARMACY AN ANNUAL REPORT IDENTIFYING ALL PAYMENTS, HONORARIA, REIMBURSEMENT OTHER COMPENSATION AUTHORIZED UNDER SECTION 151.461, CLAUSES (3) TO (5), PAID TO PRACTITIONERS IN MINNESOTA DURING THE PRECEDING CALENDAR YEAR. THE REPORT SHALL IDENTIFY THE NATURE AND VALUE OF ANY PAYMENTS TOTTALLING \$100 OR MORE, TO A PARTICULAR PRACTITIONER DURING THE YEAR, AND SHALL IDENTIFY THE PRACTITIONER, REPORTS FILED UNDER THIS PROVISION ARE PUBLIC DATA.</b>		
<b>NAME OF PRACTITIONER Please include designation (i.e., MD, etc.)</b>	<b>ADDRESS OF PRACTITIONER</b>	<b>VALUE OF PAYMENTS</b>	<b>TYPE OF PAYMENTS</b>
Metro Minnesota ONS Center	St. Paul, MN	300.00	Professional Meeting Support
Southeast Minnesota Chapter of ONS	Minnesota	300.00	Exhibit Fee
Minnesota Society of Clinical Oncology	Minneapolis, MN	250.00	Exhibit Fee
Louann Bosmans, Nurse Practitioner	Minnesota	2250.00	Speaker Honoraria
Dr. Bibi Khoyratty	Minnesota	1500.00	Speaker Honoraria

<b>NAME OF WHOLESALE DRUG DISTRIBUTOR/MANUFACTURER</b> Abraxis Bioscience Inc.		<b>ADDRESS OF WHOLESALE DRUG DISTRIBUTOR/MANUFACTURER</b> 11755 Wilshire Blvd. Suite 2000, 20 <sup>th</sup> Floor, Los Angeles, CA 90025	
<b>MN BOARD OF PHARMACY LICENSE NUMBER</b> Abraxis BioScience- Manufacturer #460011	<b>MINNESOTA STATUTES REQUIRE WHOLESALE DISTRIBUTORS TO FILE WITH THE BOARD OF PHARMACY AN ANNUAL REPORT IDENTIFYING ALL PAYMENTS, HONORARIA, REIMBURSEMENT OTHER COMPENSATION AUTHORIZED UNDER SECTION 151.461, CLAUSES (3) TO (5), PAID TO PRACTITIONERS IN MINNESOTA DURING THE PRECEDING CALENDAR YEAR. THE REPORT SHALL IDENTIFY THE NATURE AND VALUE OF ANY PAYMENTS TOTTALLING \$100 OR MORE, TO A PARTICULAR PRACTITIONER DURING THE YEAR, AND SHALL IDENTIFY THE PRACTITIONER, REPORTS FILED UNDER THIS PROVISION ARE PUBLIC DATA.</b>		
<b>NAME OF PRACTITIONER Please include designation (i.e., MD, etc.)</b>	<b>ADDRESS OF PRACTITIONER</b>	<b>VALUE OF PAYMENTS</b>	<b>TYPE OF PAYMENTS</b>
Metro Minnesota ONS Center	St. Paul, MN	600.00	Exhibit Fees
Dr. Alex Adjei	Mayo Clinic College of Medicine, Division of Medical Oncology, Rochester MN	1000.00	Advisory Board Honoraria